201 related articles for article (PubMed ID: 7841052)
1. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer.
Scambia G; Testa U; Benedetti Panici P; Foti E; Martucci R; Gadducci A; Perillo A; Facchini V; Peschle C; Mancuso S
Br J Cancer; 1995 Feb; 71(2):354-6. PubMed ID: 7841052
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer.
Nagele F; Petru E; Medl M; Kainz C; Graf AH; Sevelda P
Obstet Gynecol; 1995 Aug; 86(2):259-64. PubMed ID: 7617357
[TBL] [Abstract][Full Text] [Related]
3. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
6. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
7. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.
Kong SY; Han MH; Yoo HJ; Hwang JH; Lim MC; Seo SS; Yoo CW; Kim JH; Park SY; Kang S
Ann Surg Oncol; 2012 May; 19(5):1707-12. PubMed ID: 21833668
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
9. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
10. Serum neopterin levels in ovarian tumors.
Park IS; Lee YS; Kim JC; Hwang SG
Int J Gynaecol Obstet; 1995 Dec; 51(3):229-34. PubMed ID: 8745088
[TBL] [Abstract][Full Text] [Related]
11. Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma.
Akahiro J; Konno R; Ito K; Okamura K; Yaegashi N
Int J Clin Oncol; 2004 Feb; 9(1):42-6. PubMed ID: 15162825
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
[TBL] [Abstract][Full Text] [Related]
13. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
15. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
[TBL] [Abstract][Full Text] [Related]
16. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
17. Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer.
Zeimet AG; Natoli C; Herold M; Fuchs D; Windbichler G; Daxenbichler G; Iacobelli S; Dapunt O; Marth C
Int J Cancer; 1996 Sep; 68(1):34-8. PubMed ID: 8895537
[TBL] [Abstract][Full Text] [Related]
18. Preoperative value of CA 125 as a reflection of tumor grade in epithelial ovarian cancer.
But I; Gorisek B
Gynecol Oncol; 1996 Nov; 63(2):166-72. PubMed ID: 8910622
[TBL] [Abstract][Full Text] [Related]
19. Serum IL-6 and IL-8 Correlate with Prognostic Factors in Ovarian Cancer.
Sanguinete MMM; Oliveira PH; Martins-Filho A; Micheli DC; Tavares-Murta BM; Murta EFC; Nomelini RS
Immunol Invest; 2017 Oct; 46(7):677-688. PubMed ID: 28872976
[TBL] [Abstract][Full Text] [Related]
20. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
